Advanced Accelerator Applications (NASDAQ: AAAP) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its peers? We will compare Advanced Accelerator Applications to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Advanced Accelerator Applications and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Accelerator Applications 0 1 4 0 2.80
Advanced Accelerator Applications Competitors 99 378 987 28 2.63

Advanced Accelerator Applications presently has a consensus price target of $56.50, suggesting a potential downside of 13.28%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 19.28%. Given Advanced Accelerator Applications’ peers higher possible upside, analysts clearly believe Advanced Accelerator Applications has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Advanced Accelerator Applications and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Advanced Accelerator Applications N/A N/A -74.03
Advanced Accelerator Applications Competitors $2.57 billion $977.16 million 1.09

Advanced Accelerator Applications’ peers have higher revenue and earnings than Advanced Accelerator Applications. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Advanced Accelerator Applications and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanced Accelerator Applications -33.83% -16.05% -11.18%
Advanced Accelerator Applications Competitors -538.85% -41.85% -24.81%

Institutional and Insider Ownership

37.5% of Advanced Accelerator Applications shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Advanced Accelerator Applications has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Advanced Accelerator Applications’ peers have a beta of 0.85, suggesting that their average stock price is 15% less volatile than the S&P 500.

Summary

Advanced Accelerator Applications beats its peers on 6 of the 11 factors compared.

About Advanced Accelerator Applications

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Receive News & Stock Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related stocks with our FREE daily email newsletter.